In this image made from video, Australian Prime Minister Scott Morrison speaks during a news conference in Canberra, Australia, Thursday, April 8, 2021. Australia on Thursday become the latest country to restrict use of the AstraZeneca vaccine by recommending that it not be given to people under age 50. (SBS via AP)
In this image made from video, Australian Prime Minister Scott Morrison, right, with Australian Chief Medical Officer Paul Kelly, speaks during a news conference in Canberra, Australia, Thursday, April 8, 2021. Australia on Thursday become the latest country to restrict use of the AstraZeneca vaccine by recommending that it not be given to people under age 50. (SBS via AP)
Australian Prime Minister Scott Morrison, left, addresses the media at a press conference as Department of Health Secretary Dr Brendan Murphy watches at Parliament House in Canberra, Australia, Friday, April 9, 2021. Australia says it has finalized a deal to buy an extra 20 million doses of the Pfizer vaccine as the nation rapidly pivots away from its earlier plan to rely mainly on the AstraZeneca vaccine. (Mick Tsikas/AAP Image via AP)
CANBERRA, Australia (AP) — Australia said Friday that it has finalized a deal to buy an extra 20 million doses of the Pfizer vaccine as it rapidly pivots away from its earlier plan to rely mainly on the AstraZeneca vaccine.
Prime Minister Scott Morrison announced the deal just hours after saying Australia would stop using the AstraZeneca vaccine for people aged under 50.
He said the deal means Australia will get a total of 40 million doses of the Pfizer vaccine by the end of the year, enough to inoculate 20 million people in the nation of 26 million.
Australia's pivot came after the European Medicines Agency said this week it had found a “possible link” between the AstraZeneca vaccine and rare blood clots, though regulators in the United Kingdom and the European Union emphasized that the benefits of receiving the vaccine continue to outweigh the risks for most people.
After the European agency's declaration, Australian drug regulators held a series of urgent meetings Thursday and recommended the Pfizer vaccine become the preferred vaccine for people under 50.
Morrison said there was no prohibition on the AstraZeneca vaccine and the risk of side effects was remote. He said the change was being made out of an abundance of caution.
The pivot represents a significant shift in Australia's overall approach and is likely to delay plans to have everybody inoculated by October.
A major part of Australia’s strategy had been the ability to make its own vaccines at home and not rely on shipments from abroad. It had planned to manufacture some 50 million doses of the AstraZeneca vaccine, enough for 25 million people. Australia had made no plans to make any other vaccines at home.
Even before the change, the government was facing criticism for a rollout program that's lagging behind those in most other developed nations. So far, Australia has administered just over 1 million vaccine doses.
Opposition Leader Anthony Albanese said the rollout was a debacle and Australians needed certainty about when they would be vaccinated.
“This government has failed. This government couldn’t run a choko vine up a back fence,” Albanese told reporters, referring to a plant that produces pear-shaped fruit and grows easily in the Australian climate.
Health Minister Greg Hunt said there would be some adjustments but everybody would be kept safe and would get vaccinated.
Australia has managed to stamp out community spread of the virus, allowing life to continue much as before the pandemic.
AstraZeneca noted Australia’s decision to restrict the vaccine's use was based on it having no community transmission.
“Overall, regulatory agencies have reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks,” the company said in a statement.
Featured Article: Systematic Risk and Investors
7 Precious Metals Stocks That Will Keep Your Portfolio On TrendThe growing acceptance of cryptocurrency is beginning to make mainstream investors rethink their idea of “store of value.” The trendy possibilities of Bitcoin, Ethereum, and any of the dozens of altcoins that exist on the blockchain are trending like the latest fashion.
However, the thing about fashion is that the more things change the more things stay the same. Just like the simple black dress that won’t go out of fashion, the same can be said for precious metals stocks. One way to think about it would be to say that the existence of a growing cryptocurrency market doesn’t change the value of precious metals.
Precious metals have long been known to be a safe-haven asset in times of market volatility and economic crisis. In fact, during the Covid-19 pandemic, gold prices surged about 30% breaking the $2,000 mark for the first time in its history. This was at a time when the prices of many cryptocurrencies were falling.
And precious metals have also been seen as a hedge against inflation, which seems like more of a certainty with the Federal Reserve’s pledge to keep interest rates at historically low rates into 2023.
Whether you’re looking to take your first steps at crafting a precious metals portfolio or if you want to fine-tune the one you have, we believe this special presentation is a good place to start your research. We’ve identified seven precious metals stocks that look to retain their allure in 2021.
View the "7 Precious Metals Stocks That Will Keep Your Portfolio On Trend".
Companies Mentioned in This Article
Compare These Stocks Add These Stocks to My Watchlist
